Translational sciences approach to RSV vaccine development

References

• Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. 92(3), 544–549 (1956).
   PubMed Web of Science ®Google Scholar
• Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Res. 162(1–2), 80–99. (2011).
   PubMedGoogle Scholar
• Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63(7), 2941–2950 (1989).
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Leung S et al.Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340(6136), 1113–1117 (2013).
   PubMed Web of Science ®Google Scholar
• McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85(15), 7788–7796 (2011).
   PubMed Web of Science ®Google Scholar
• Connors M, Collins PL, Firestone CY, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65(3), 1634–1637 (1991).
   PubMed Web of Science ®Google Scholar
• Hendricks DA, McIntosh K, Patterson JL. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J. Virol. 62(7), 2228–2233 (1988).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Yang L, Fricke J et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82(24), 12191–12204 (2008).
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2(8), 732–738 (2001).
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 375(9725), 1545–1555 (2010).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 282(15), 1440–1446 (1999).
   PubMed Web of Science ®Google Scholar
• Mutuc JD, Langley GE. Respiratory Syncytial Virus - United States, July 2007 – June 2011. MMWR 60(35), 1203 (2011).
   Google Scholar
• Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140(6), 543–546 (1986).
   PubMedGoogle Scholar
• Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360(6), 588–598 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou H, Thompson WW, Viboud CG et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States. 1993–2008. Clin. Infect. Dis. 54(10), 1427–1436 (2012).
   PubMed Web of Science ®Google Scholar
• Iwane MK, Edwards KM, Szilagyi PG et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 113(6), 1758–1764 (2004).
   PubMed Web of Science ®Google Scholar
• Fryzek JP, Martone WJ, Groothuis JR. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study. Adv. Ther. 28(3), 195–201 (2011).
   PubMedGoogle Scholar
• Groothuis JR, Fryzek JP, Makari D, Steffey D, Martone WJ. Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998–2008. Clin. Epidemiol. 3, 245–250 (2011).
   Google Scholar
• Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children. 1979–1997. J. Infect. Dis. 183(1), 16–22 (2001).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352(17), 1749–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging 22(7), 577–587 (2005).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR, Hennessey PA. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am. J. Respir. Crit. Care Med. 160(3), 791–795 (1999).
   PubMedGoogle Scholar
• Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin. Infect. Dis. 33(6), 792–796 (2001).
   PubMed Web of Science ®Google Scholar
• Sorvillo FJ, Huie SF, Strassburg MA, Butsumyo A, Shandera WX, Fannin SL. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly. J. Infect. 9(3), 252–256 (1984).
   PubMed Web of Science ®Google Scholar
• Vikerfors T, Grandien M, Olcen P. Respiratory syncytial virus infections in adults. Am. Rev. Respir. Dis. 136(3), 561–564 (1987).
   PubMed Web of Science ®Google Scholar
• Falsey AR, McCann RM, Hall WJ et al. Acute respiratory tract infection in daycare centers for older persons. J. Am. Geriatr. Soc. 43(1), 30–36 (1995).
   PubMed Web of Science ®Google Scholar
• Dowell SF, Anderson LJ, Gary HE Jr, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174(3), 456–462 (1996).
   PubMed Web of Science ®Google Scholar
• Anak S, Atay D, Unuvar A et al. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. Pediatr. Pulmonol. 45(3), 307–311 (2010).
   PubMed Web of Science ®Google Scholar
• El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics 121(2), 235–243 (2008).
   PubMed Web of Science ®Google Scholar
• Small TN, Casson A, Malak SF et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant. 29(4), 321–327 (2002).
   PubMedGoogle Scholar
• Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet. 358(9291), 1410–1416 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper DL, Smith GE, Edmunds WJ, Joseph C, Gerard E, George RC. The contribution of respiratory pathogens to the seasonality of NHS Direct calls. J. Infect. 55(3), 240–248 (2007).
   PubMedGoogle Scholar
• Fleming DM, Cross KW. Respiratory syncytial virus or influenza? Lancet 342(8886–8887), 1507–1510 (1993).
   Google Scholar
• Nicholson KG. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol. Infect. 116(1), 51–63 (1996).
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. Census 2000 Summary File1 and 2010 Census Summary File 1. (May 1).
   Google Scholar
• U.S. Census Bureau. 2010 Census. Summary File 1, Table PCT12. (May 1).
   Google Scholar
• Mullooly JP, Bridges CB, Thompson WW et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 25(5), 846–855 (2007).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 315(7115), 1060–1064 (1997).
   PubMedGoogle Scholar
• DeVincenzo JP, Wilkinson T, Vaishnaw A et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 182(10), 1305–1314 (2010).
   PubMed Web of Science ®Google Scholar
• El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J. Infect. Dis. 204(7), 996–1002 (2011).
   PubMed Web of Science ®Google Scholar
• Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 168(6), 633–639 (2003).
   PubMed Web of Science ®Google Scholar
• Polack FP, Teng MN, Collins PL et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196(6), 859–865 (2002).
   PubMed Web of Science ®Google Scholar
• Aung S, Rutigliano JA, Graham BS. Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease. J. Virol. 75(20), 9918–9924 (2001).
   PubMed Web of Science ®Google Scholar
• Zeng R, Li C, Li N, Wei L, Cui Y. The role of cytokines and chemokines in severe respiratory syncytial virus infection and subsequent asthma. Cytokine 53(1), 1–7 (2011).
   PubMedGoogle Scholar
• Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 82(5), 2040–2055 (2008).
   PubMed Web of Science ®Google Scholar
• Houben ML, Coenjaerts FE, Rossen JW et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J. Med. Virol. 82(7), 1266–1271 (2010).
   PubMed Web of Science ®Google Scholar
• Fodha I, Vabret A, Ghedira L et al. Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity. J. Med. Virol. 79(12), 1951–1958 (2007).
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J. Infect. Dis. 191(11), 1861–1868 (2005).
   PubMed Web of Science ®Google Scholar
• Buckingham SC, Bush AJ, Devincenzo JP. Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants. Pediatr. Infect. Dis. J. 19(2), 113–117 (2000).
   PubMed Web of Science ®Google Scholar
• Duncan CB, Walsh EE, Peterson DR, Lee FE, Falsey AR. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J. Infect. Dis. 200(8), 1242–1246 (2009).
   PubMed Web of Science ®Google Scholar
• Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 300(10), 530–534 (1979).
   PubMed Web of Science ®Google Scholar
• Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163(4), 693–698 (1991).
   PubMed Web of Science ®Google Scholar
• Wagner DK, Graham BS, Wright PF et al. Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J. Clin. Microbiol. 24(2), 304–306 (1986).
   PubMed Web of Science ®Google Scholar
• Wagner DK, Muelenaer P, Henderson FW et al. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections. J. Clin. Microbiol. 27(3), 589–592 (1989).
   PubMed Web of Science ®Google Scholar
• Wagner DK, Nelson DL, Walsh EE, Reimer CB, Henderson FW, Murphy BR. Differential immunoglobulin G subclass antibody titers to respiratory syncytial virus F and G glycoproteins in adults. J. Clin. Microbiol. 25(4), 748–750 (1987).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J. Med. Virol. 78(11), 1493–1497 (2006).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Graham BS, Prince GA et al.Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J. Clin. Microbiol. 23(6), 1009–1014 (1986).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J. Infect. Dis. 190(2), 373–378 (2004).
   PubMed Web of Science ®Google Scholar
• Stensballe LG, Ravn H, Kristensen K et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J. Allergy Clin. Immunol. 123(2), 398–403 (2009).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J. Infect. Dis. 177(2), 463–466 (1998).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21(24), 3479–3482 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J. Infect. Dis. 189(2), 233–238 (2004).
   PubMed Web of Science ®Google Scholar
• Luchsinger V, Piedra PA, Ruiz M et al. Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus. Clin. Infect. Dis. (2012).
   PubMedGoogle Scholar
• Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res. 63(3), 191–196 (2004).
   PubMed Web of Science ®Google Scholar
• Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 99(1), 93–99 (1997).
   PubMedGoogle Scholar
• Siber GR, Leszcynski J, Pena-Cruz V et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J. Infect. Dis. 165(3), 456–463 (1992).
   PubMed Web of Science ®Google Scholar
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics 102(3), 531–537 (1998).
   Web of Science ®Google Scholar
• Carbonell-Estrany X, Simoes EA, Dagan R et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125(1), e35–e51 (2010).
   PubMed Web of Science ®Google Scholar
• Wu P, Hartert TV. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev. Anti Infect. Ther. 9(9), 731–745 (2011).
   Google Scholar
• Blanken MO, Rovers MM, Molenaar JM et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N. Engl. J. Med. 368(19), 1791–1799 (2013).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE, Looney RJ et al. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J. Med. Virol. 59(2), 221–226 (1999).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J. Med. Virol. 73(2), 295–299 (2004).
   PubMed Web of Science ®Google Scholar
• Terrosi C, Di Genova G, Martorelli B, Valentini M, Cusi MG. Humoral immunity to respiratory syncytial virus in young and elderly adults. Epidemiol. Infect. 137(12), 1684–1686 (2009).
   PubMed Web of Science ®Google Scholar
• Eick A, Karron R, Shaw J et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr. Infect. Dis. J. 27(3), 207–212 (2008).
   PubMed Web of Science ®Google Scholar
• Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J. Med. Virol. 7(4), 263–271 (1981).
   PubMed Web of Science ®Google Scholar
• Roca A, Abacassamo F, Loscertales MP et al. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J. Med. Virol. 67(4), 616–623 (2002).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98(5), 708–715 (1981).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Alling DW, Snyder MH et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J. Clin. Microbiol. 24(5), 894–898 (1986).
   PubMed Web of Science ®Google Scholar
• Shinoff JJ, O'Brien KL, Thumar B et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J. Infect. Dis. 198(7), 1007–1015 (2008).
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Tsutsumi H, Matsuda K, Nagai K, Ogra PL, Chiba S. Effect of maternal antibody on IgA antibody response in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection. J. Gen. Virol. 75 (Pt 8), 2115–2119 (1994).
   PubMedGoogle Scholar
• Lewis DB, Wilson CB. CHAPTER 4 - Developmental Immunology and Role of Host Defenses in Fetal and Neonatal Susceptibility to Infection. In: Infectious Diseases of the Fetus and Newborn (7th Edition). Anonymous WB (ED). Saunders, Philadelphia, 80–191 (2011).
   Google Scholar
• De Alarcon A, Walsh EE, Carper HT et al. Detection of IgA and IgG but not IgE antibody to respiratory syncytial virus in nasal washes and sera from infants with wheezing. J. Pediatr. 138(3), 311–317 (2001).
   PubMedGoogle Scholar
• Jensen IP, Thisted E, Glikmann G et al. Secretory IgM and IgA antibodies to respiratory syncytial virus in nasopharyngeal aspirates: a diagnostic supplement to antigen detection. Clin. Diagn. Virol. 8(3), 219–226 (1997).
   PubMedGoogle Scholar
• Okiro EA, Sande C, Mutunga M, Medley GF, Cane PA, Nokes DJ. Identifying infections with respiratory syncytial virus by using specific immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays with oral-fluid samples. J. Clin. Microbiol. 46(5), 1659–1662 (2008).
   PubMedGoogle Scholar
• Yamazaki H, Tsutsumi H, Matsuda K, Nagai K, Ogra PL, Chiba S. Respiratory syncytial virus group-specific antibody response in nasopharyngeal secretions from infants and children after primary infection. Clin. Diagn. Lab. Immunol. 1(4), 469–472 (1994).
   PubMedGoogle Scholar
• Steinhoff MC, Hall CB, Schnabel KC. Respiratory syncytial virus serology by a simplified enzyme-linked immunosorbent assay. J. Clin. Microbiol. 12(3), 447–450 (1980).
   PubMedGoogle Scholar
• Zielinska E, Liu D, Wu HY, Quiroz J, Rappaport R, Yang DP. Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis. Virol. J. 2, 84 (2005).
   PubMedGoogle Scholar
• Anderson LJ, Hierholzer JC, Bingham PG, Stone YO. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 22(6), 1050–1052 (1985).
   PubMedGoogle Scholar
• Chen M, Chang JS, Nason M et al. A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. J. Immunol. Methods. 362(1–2), 180–184 (2010).
   PubMedGoogle Scholar
• Swanson KA, Settembre EC, Shaw CA et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl Acad. Sci. USA 108(23), 9619–9624 (2011).
   Google Scholar
• Glenn GM, Smith G, Fries L et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 31(3), 524–532 (2012).
   PubMed Web of Science ®Google Scholar
• Agius G, Dindinaud G, Biggar RJ et al. An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J. Med. Virol. 30(2), 117–127 (1990).
   PubMedGoogle Scholar
• Jones LP, Zheng HQ, Karron RA, Peret TC, Tsou C, Anderson LJ. Multiplex assay for detection of strain-specific antibodies against the two variable regions of the G protein of respiratory syncytial virus. Clin. Diagn. Lab. Immunol. 9(3), 633–638 (2002).
   PubMedGoogle Scholar
• Anderson S, Wakeley P, Wibberley G, Webster K, Sawyer J. Development and evaluation of a Luminex multiplex serology assay to detect antibodies to bovine herpes virus 1, parainfluenza 3 virus, bovine viral diarrhoea virus, and bovine respiratory syncytial virus, with comparison to existing ELISA detection methods. J. Immunol. Methods 366(1–2), 79–88 (2011).
   PubMedGoogle Scholar
• Opalka D, Matys K, Bojczuk P et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin. Vaccine Immunol. 17(5), 818–827 (2010).
   PubMedGoogle Scholar
• Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J. Pediatr. 96(2), 179–186 (1980).
   PubMed Web of Science ®Google Scholar
• Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med. 315(2), 77–81 (1986).
   PubMed Web of Science ®Google Scholar
• Bont L, Versteegh J, Swelsen WT et al. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr. Res. 52(3), 363–367 (2002).
   PubMed Web of Science ®Google Scholar
• Lukens MV, van de Pol AC, Coenjaerts FE et al. A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J. Virol. 84(5), 2374–2383 (2010).
   PubMed Web of Science ®Google Scholar
• Heidema J, Lukens MV, van Maren WW et al. CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J. Immunol. 179(12), 8410–8417 (2007).
   PubMed Web of Science ®Google Scholar
• Welliver TP, Garofalo RP, Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis. 195(8), 1126–1136 (2007).
   PubMed Web of Science ®Google Scholar
• Larranaga CL, Ampuero SL, Luchsinger VF et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr. Infect. Dis. J. 28(10), 867–873 (2009).
   PubMedGoogle Scholar
• Mbawuike IN, Wells J, Byrd R, Cron SG, Glezen WP, Piedra PA. HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-gamma, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J. Infect. Dis. 183(5), 687–696 (2001).
   PubMed Web of Science ®Google Scholar
• Looney RJ, Falsey AR, Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J. Infect. Dis. 185(5), 682–685 (2002).
   PubMed Web of Science ®Google Scholar
• Lee FE, Walsh EE, Falsey AR et al. The balance between influenza- and RSV-specific CD4 T cells secreting IL-10 or IFNgamma in young and healthy-elderly subjects. Mech. Ageing Dev. 126(11), 1223–1229 (2005).
   PubMedGoogle Scholar
• de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, van Lier RA. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J. Exp. Med. 202(10), 1433–1442 (2005).
   PubMed Web of Science ®Google Scholar
• de Bree GJ, Heidema J, van Leeuwen EM et al. Respiratory syncytial virus-specific CD8+ memory T cell responses in elderly persons. J. Infect. Dis. 191(10), 1710–1718 (2005).
   PubMed Web of Science ®Google Scholar
• de Bree GJ, Daniels H, Schilfgaarde M et al. Characterization of CD4+ memory T cell responses directed against common respiratory pathogens in peripheral blood and lung. J. Infect. Dis. 195(11), 1718–1725 (2007).
   PubMedGoogle Scholar
• Cusi MG, Martorelli B, Di Genova G, Terrosi C, Campoccia G, Correale P. Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects. Immun. Ageing 7, 14 (2010).
   PubMedGoogle Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 39(1–3), 225–239 (2007).
   PubMedGoogle Scholar
• Bendelja K, Gagro A, Bace A et al. Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry. Clin. Exp. Immunol. 121(2), 332–338 (2000).
   PubMed Web of Science ®Google Scholar
• Byeon JH, Lee JC, Choi IS, Yoo Y, Park SH, Choung JT. Comparison of cytokine responses in nasopharyngeal aspirates from children with viral lower respiratory tract infections. Acta. Paediatr. 98(4), 725–730 (2009).
   PubMedGoogle Scholar
• Kristjansson S, Bjarnarson SP, Wennergren G et al. Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. J. Allergy Clin. Immunol. 116(4), 805–811 (2005).
   Google Scholar
• Lee FE, Walsh EE, Falsey AR et al. Human infant respiratory syncytial virus (RSV)-specific type 1 and 2 cytokine responses ex vivo during primary RSV infection. J. Infect. Dis. 195(12), 1779–1788 (2007).
   PubMedGoogle Scholar
• Lindemans CA, Kimpen JL, Luijk B et al. Systemic eosinophil response induced by respiratory syncytial virus. Clin. Exp. Immunol. 144(3), 409–417 (2006).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Mao JH, Du LZ, Tang YM. Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection. Acta Paediatr. 91(9), 914–922 (2002).
   PubMedGoogle Scholar
• de Waal L, Koopman LP, van Benten IJ et al. Moderate local and systemic respiratory syncytial virus-specific T-cell responses upon mild or subclinical RSV infection. J. Med. Virol. 70(2), 309–318 (2003).
   PubMedGoogle Scholar
• van Benten IJ, van Drunen CM, Koopman LP et al. RSV-induced bronchiolitis but not upper respiratory tract infection is accompanied by an increased nasal IL-18 response. J. Med. Virol. 71(2), 290–297 (2003).
   PubMedGoogle Scholar
• Choi EH, Lee HJ, Yoo T, Chanock SJ. A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J. Infect. Dis. 186(9), 1207–1211 (2002).
   PubMedGoogle Scholar
• Hoebee B, Rietveld E, Bont L et al. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. J. Infect. Dis. 187(1), 2–11 (2003).
   PubMedGoogle Scholar
• Forton JT, Rowlands K, Rockett K et al. Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster. Thorax. 64(4), 345–352 (2009).
   PubMed Web of Science ®Google Scholar
• Puthothu B, Krueger M, Forster J, Heinzmann A. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J. Infect. Dis. 193(3), 438–441 (2006).
   PubMedGoogle Scholar
• Gentile DA, Doyle WJ, Zeevi A et al. Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum. Immunol. 64(3), 338–344 (2003).
   PubMedGoogle Scholar
• Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J. Infect. Dis. 184(4), 393–399 (2001).
   PubMed Web of Science ®Google Scholar
• Gonzalez PA, Bueno SM, Riedel CA, Kalergis AM. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis. Curr. Med. Chem. 16(34), 4609–4625 (2009).
   PubMed Web of Science ®Google Scholar
• Cherukuri A, Patton K, Gasser R Jr, et al. Adults 65 Years and Older Have Reduced Functional Memory T Cells to Respiratory Synctial Virus Fusion (F) Protein. 2012. Clin. Vaccine Immunol. 20(2), 239–247 (2013).
   PubMedGoogle Scholar
• Kierstead LS, Dubey S, Meyer B et al. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res. Hum. Retroviruses 23(1), 86–92 (2007).
   PubMedGoogle Scholar
• Kern F, LiPira G, Gratama JW, Manca F, Roederer M. Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol. 26(9), 477–484 (2005).
   PubMedGoogle Scholar
• Mashishi T, Gray CM. The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin. Chem. Lab. Med. 40(9), 903–910 (2002).
   PubMedGoogle Scholar
• Slota M, Lim JB, Dang Y, Disis ML. ELISpot for measuring human immune responses to vaccines. Expert Rev. Vaccines 10(3), 299–306 (2011).
   PubMed Web of Science ®Google Scholar
• Patton K, Aslam S, Lin J et al. Detection of Human RSV F-Specific IFNg Producing T Cells Using a Qualified Enzyme-Linked Immunosorbent Spot Assay. Submitted (2013).
   Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8(4), 247–258 (2008).
   PubMed Web of Science ®Google Scholar
• Chattopadhyay PK, Roederer M. Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease. Cytometry A. 77(7), 614–622 (2010).
   PubMedGoogle Scholar
• Davis MM, Altman JD, Newell EW. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat. Rev. Immunol. 11(8), 551–558 (2011).
   PubMed Web of Science ®Google Scholar
• Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM. New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev. Vaccines 9(6), 601–616 (2010).
   PubMed Web of Science ®Google Scholar
• Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J. Pediatr. 89(1), 11–15 (1976).
   PubMed Web of Science ®Google Scholar
• Hall WJ, Hall CB, Speers DM. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann. Intern. Med. 88(2), 203–205 (1978).
   PubMedGoogle Scholar
• Kim SR, Ki CS, Lee NY. Rapid detection and identification of 12 respiratory viruses using a dual priming oligonucleotide system-based multiplex PCR assay. J. Virol. Methods 156(1–2), 111–116 (2009).
   PubMedGoogle Scholar
• Sanghavi SK, Bullotta A, Husain S, Rinaldo CR. Clinical evaluation of multiplex real-time PCR panels for rapid detection of respiratory viral infections. J. Med. Virol. 84(1), 162–169 (2012).
   PubMedGoogle Scholar
• Englund JA, Piedra PA, Jewell A, Patel K, Baxter BB, Whimbey E. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J. Clin. Microbiol. 34(7), 1649–1653 (1996).
   PubMedGoogle Scholar
• Casiano-Colon AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J. Clin. Virol. 28(2), 169–174 (2003).
   PubMed Web of Science ®Google Scholar
• Falsey AR. Respiratory syncytial virus infection in adults. Semin. Respir. Crit. Care. Med. 28(2), 171–181 (2007).
   PubMedGoogle Scholar
• Henrickson KJ, Hall CB. Diagnostic assays for respiratory syncytial virus disease. Pediatr. Infect. Dis. J. 26(Suppl. 11), S36–40 (2007).
   PubMedGoogle Scholar
• Falsey AR, Formica MA, Walsh EE. Yield of sputum for viral detection by reverse transcriptase PCR in adults hospitalized with respiratory illness. J. Clin. Microbiol. 50(1), 21–24 (2012).
   PubMed Web of Science ®Google Scholar
• Ohrt C, Purnomo, Sutamihardja MA, Tang D, Kain KC. Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials. J. Infect. Dis. 186(4), 540–546 (2002).
   PubMed Web of Science ®Google Scholar
• Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum. Vaccin. 5(9), 582–591 (2009).
   PubMed Web of Science ®Google Scholar
• Murata Y. Respiratory syncytial virus vaccine development. Clin. Lab. Med. 29(4), 725–739 (2009).
   PubMed Web of Science ®Google Scholar
• MedImmune. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children. (2012).
   Google Scholar
• Karron RA, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191(7), 1093–1104 (2005).
   PubMed Web of Science ®Google Scholar
• Karron RA, Thumar B, Schappell E, Buchholz UJ, Collins PL. Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines. J. Infect. Dis. 207(11), 1773–1779 (2013).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Malkin E, Abughali N et al. Phase 1 study of the safety and immunogenicity of a Live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr. Infect. Dis. J. (2011).
   Google Scholar
• Cheng X, Zhou H, Tang RS, Munoz MG, Jin H. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys. Virology 283(1), 59–68 (2001).
   PubMedGoogle Scholar
• NIAID. Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children. (2012).
   Google Scholar
• Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi. Viruses 5(2), 67–75 (2011).
   Google Scholar
• Siegrist CA. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol. 137(Suppl. 1), S4–S9 (2007).
   PubMedGoogle Scholar
• Falsey AR, Walsh EE, Capellan J et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. J. Infect. Dis. 198(9), 1317–1326 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Siber GR. Adjuvants for human vaccines – current status, problems and future prospects. Vaccine 13(14), 1263–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4(8), 648–655 (2004).
   PubMed Web of Science ®Google Scholar
• Miconnet I. Probing the T-cell receptor repertoire with deep sequencing. Curr. Opin. HIV AIDS 7(1), 64–70 (2012).
   PubMedGoogle Scholar